AURICULARUM (oxytetracycline, polymyxin B, dexamethasone, nystatin), fixed combination of antibiotics, antifungal and corticosteroid

TRANSPARENCY COMMITTEE OPINION
Opinions on drugs - Posted on Apr 14 2016

Reason for request

Renweal of inclusion

Very limited role in the treatment of otitis externa and chronic otitis

  • AURICULARUM has Marketing Authorization in the topical treatment of bacterial and/or fungal otitis externa and in chronic otitis for pre-operative draining or for post-operative use in the petro-mastoid canal, with or without tympanoplasty.
  • Its actual benefit is moderate and it has a limited role in the treatment of otitis externa.

 


Clinical Benefit

Moderate

-


Therapeutic use

-

Contact Us

Évaluation des médicaments